Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Cervarix in Healthy Female Children 4-6 Years Old
NCT01627561Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2012
- Primary completion
- Apr 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, single-blind trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection (2 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Any and Grade 3 Solicited Local Symptoms, Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms and 4 more. Started Oct 2012; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT01627561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01627561.